Pharmacodynamics of dose-escalated 'front-loading' polymyxin B regimens against polymyxin-resistant mcr-1-harbouring Escherichia coli

The Journal of Antimicrobial Chemotherapy
Nicholas M SmithBrian T Tsuji

Abstract

Gram-negative bacteria harbouring the mcr-1 plasmid are resistant to the 'last-line' polymyxins and have been reported worldwide. Our objective was to define the impact of increasing the initial polymyxin B dose intensity against an mcr-1 -harbouring strain to delineate the impact of plasmid-mediated polymyxin resistance on the dynamics of bacterial killing and resistance. A hollow fibre infection model (HFIM) was used to simulate polymyxin B regimens against an mcr-1 -harbouring Escherichia coli (MIC 8 mg/L) over 10 days. Four escalating polymyxin B 'front-loading' regimens (3.33, 6.66, 13.3 or 26.6 mg/kg for one dose followed by 1.43 mg/kg every 12 h starting 12 h later) simulating human pharmacokinetics were utilized in the HFIM. A mechanism-based, mathematical model was developed using S-ADAPT to characterize bacterial killing. The 3.33 mg/kg 'front-loading' regimen resulted in regrowth mirroring the growth control. The 6.66, 13.3 and 26.6 mg/kg 'front-loading' regimens resulted in maximal bacterial reductions of 1.91, 3.79 and 6.14 log 10 cfu/mL, respectively. Irrespective of the early polymyxin B exposure (24 h AUC), population analysis profiles showed similar growth of polymyxin B-resistant subpopulations. The HFIM data ...Continue Reading

References

Mar 4, 2011·The AAPS Journal·Jurgen Bernd BulittaCornelia Barbara Landersdorfer
May 24, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ana M SandriAlexandre P Zavascki
Feb 18, 2014·Journal of Pharmaceutical and Biomedical Analysis·Soon-Ee CheahRoger L Nation
Dec 10, 2015·Infectious Diseases and Therapy·Phillip J BergenBrian T Tsuji
Jan 18, 2016·The Lancet Infectious Diseases·Laurent PoirelPatrice Nordmann
Mar 15, 2016·The Lancet Infectious Diseases·Michael R MulveyRoberto G Melano
Mar 16, 2016·Antimicrobial Agents and Chemotherapy·Kun-Jiao ZengGuo-Bao Tian
Apr 14, 2016·Antimicrobial Agents and Chemotherapy·Brian T TsujiJian Li
May 4, 2016·South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde·Jennifer CoetzeeAdrian John Brink
May 28, 2016·Antimicrobial Agents and Chemotherapy·Patrick McGannKurt E Schaecher
Oct 22, 2016·Trends in Microbiology·Gerard D Wright
Aug 16, 2016·International Journal of Antimicrobial Agents·Sophie BaronAbiola Olumuyiwa Olaitan

❮ Previous
Next ❯

Citations

Dec 29, 2020·International Journal of Antimicrobial Agents·Hubert C ChuaBrian T Tsuji
May 11, 2020·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·N J OnufrakZ P Bulman
Feb 18, 2020·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·N M SmithB T Tsuji
Jun 8, 2021·Antimicrobial Agents and Chemotherapy·Michael MaynardArnold Louie

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.